Eli Lilly and Company operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eli Lilly and Company with three other
companies in this sector in the United States:
Teva Pharmaceutical Industries Limited
sales of $22.39 billion
of which 55%
was Generic Medicines),
Bristol-Myers Squibb Company
of which 100%
was Pharmaceuticals), and
of which 100%
Eli Lilly and Company reported sales of $22.87 billion
December of 2017.
increase of 7.8%
versus 2016, when the company's sales were $21.22 billion.
This was the third consecutive year of growth at Eli Lilly and Company.
The sales level in 2017 was fairly close to the level five years ago: in 2012, Eli Lilly and Company had sales
of $22.60 billion.
Sales of Human Pharmaceutical Products - Endocrin saw an increase
that was more than double the company's growth rate: sales were up
24.8% in 2017, from
$8.08 billion to $10.09 billion.
Not all segments of Eli Lilly and Company experienced an increase in sales in 2017:
sales of Other Pharmaceuticals fell 23.1% to $241.30 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Eli Lilly and Company also experienced decreases in sales in
Animal Health (down 2.3% to $3.09 billion)
Human Pharmaceutical Products - Cardiova (down 11.0% to $2.87 billion)
Human Pharmaceutical Products -Neuroscie (down 20.2% to $2.17 billion)